Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery

Phase 3

Terminated

• Conditions: Head and Neck Cancer
• Interventions: Drug: cisplatin; Biological: filgrastim; Drug: docetaxel; Drug: paclitaxel; Drug: fluorouracil; Radiation: radiation therapy

• Registration Number: NCT00113399
• Lead Sponsor: Radiation Therapy Oncology Group

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cisplatin and paclitaxel may make tumor cells more sensitive to radiation therapy. Giving more than one drug (combination chemotherapy) and giving them with radiation therapy may kill more tumor cells. It is not yet known whether giving radiation therapy together with combination chemotherapy is more effective than giving combination chemotherapy alone in treating head and neck cancer.

PURPOSE: This randomized phase III trial is studying radiation therapy and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating patients with recurrent head and neck cancer that cannot be removed by surgery.

Detailed Description

OBJECTIVES:

Primary

* Compare overall survival of patients with previously irradiated unresectable locally recurrent squamous cell carcinoma of the head and neck treated with radiotherapy, cisplatin, and paclitaxel vs cisplatin-based chemotherapy alone.

Secondary

* Compare progression-free survival of patients treated with these regimens.

* Compare the toxicity of these regimens in these patients.

* Compare quality of life, functional/performance status, and quality-adjusted survival of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo radiotherapy twice daily and receive paclitaxel IV over 1 hour and cisplatin IV over 30 minutes once daily on days 1-5, 15-19, 29-33, and 43-47. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 6-13, 20-27, 34-41, and 48-55.

* Arm II: Patients receive 1 of the following cisplatin-based\* regimens at the discretion of the treating physician:

* Regimen 1: Patients receive cisplatin\* IV over 1-2 hours on day 1 and fluorouracil IV continuously over 96 hours on days 1-4.

* Regimen 2: Patients receive cisplatin\* IV over 1-2 hours and paclitaxel IV over 3 hours on day 1.

* Regimen 3: Patients receive cisplatin\* IV over 1-2 hours and docetaxel IV over 1 hour on day 1.

NOTE: \*Carboplatin may be substituted for cisplatin in patients with creatinine clearance \< 50 mL/min or in patients who experience grade 2 or 3 neurotoxicity.

For all regimens, treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond documentation of CR.

Quality of life is assessed at baseline and then at 3, 6, 12, 24, and 36 months.

After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 240 patients (120 per treatment arm) will be accrued for this study within 5½ years.

Study Timeline

• Study Start: 2005-04
• Study First Submitted: 2005-06-07
• Study First Submitted QC: 2005-06-07
• Study First Posted: 2005-06-08
• Primary Completion: 2009-02
• Results First Submitted: 2012-11-27
• Results First Submitted QC: 2012-11-28
• Results First Posted: 2012-12-31
• Status Verified: 2013-06
• Last Update Submitted: 2013-06-26
• Last Update Posted: 2013-07-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Chemotherapy	cisplatin	Cisplatin/fluorouracil/paclitaxel/docetaxel
Radiotherapy and chemotherapy	filgrastim	Radiotherapy/paclitaxel/cisplatin/filgrastim
Radiotherapy and chemotherapy	radiation therapy	Radiotherapy/paclitaxel/cisplatin/filgrastim
Radiotherapy and chemotherapy	paclitaxel	Radiotherapy/paclitaxel/cisplatin/filgrastim
Radiotherapy and chemotherapy	cisplatin	Radiotherapy/paclitaxel/cisplatin/filgrastim
Chemotherapy	fluorouracil	Cisplatin/fluorouracil/paclitaxel/docetaxel
Chemotherapy	docetaxel	Cisplatin/fluorouracil/paclitaxel/docetaxel
Chemotherapy	paclitaxel	Cisplatin/fluorouracil/paclitaxel/docetaxel

Primary Outcome Measures

Name	Time	Method
Overall Survival	Date of death or last follow-up

Trial Locations

Locations (125)

University of Alabama at Birmingham Comprehensive Cancer Center; 🇺🇸 Birmingham, Alabama, United States

Mobile Infirmary Medical Center; 🇺🇸 Mobile, Alabama, United States

St. Joseph's Mercy Cancer Center; 🇺🇸 Hot Springs, Arkansas, United States

Auburn Radiation Oncology; 🇺🇸 Auburn, California, United States

Radiation Oncology Centers - Cameron Park; 🇺🇸 Cameron Park, California, United States

Mercy Cancer Center at Mercy San Juan Medical Center; 🇺🇸 Carmichael, California, United States

Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center; 🇺🇸 Pomona, California, United States

Radiation Oncology Center - Roseville; 🇺🇸 Roseville, California, United States

Radiological Associates of Sacramento Medical Group, Incorporated; 🇺🇸 Sacramento, California, United States

University of California Davis Cancer Center; 🇺🇸 Sacramento, California, United States

Scroll for more (115 remaining)